Oren Gilad is CEO & President at Aprea Therapeutics, Inc. (APRE). They have made 6 open-market trades across 1 company since 2024, most recently 2026-03-12.
CIK 0001929300
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $55K since 2024, never a sale. Across 6 scored buys the stock is down 3.3% at ninety days, and 10.2 points behind the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| APRE | 393,895 | $231K |
Shares reported on the most recent Form 4, priced at the 2026-03-16 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 50% | 33% |
| Avg Move | -1.7% | -3.4% | -3.3% |
| Alpha | -2.6% | -6.3% | -10.2% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APRE | BUY | 2026-01-30 | 2026-02-02 | $0.89 | $25K | -16.5% | +28.3% | +18.9% |
| APRE | BUY | 2025-04-03 | 2025-04-04 | $1.84 | $10K | -3.3% | +10.1% | +9.4% |
| APRE | BUY | 2024-10-23 | 2024-10-24 | $3.92 | $2K | -4.7% | -28.1% | -1.0% |
| APRE | BUY | 2024-10-15 | 2024-10-16 | $2.90 | $725 | +13.8% | -13.6% | -3.7% |
| APRE | BUY | 2024-10-10 | 2024-10-15 | $2.58 | $3K | -5.6% | -22.5% | -20.8% |
| APRE | BUY | 2024-03-13 | 2024-03-14 | $7.29 | $15K | +5.9% | +5.5% | -22.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.